TABLE 1.
Effect of glycol splitting by periodate treatment on inhibitory activity of heparin against merozoite invasion in growth inhibition assaysa
| Parent compound | % inhibition (SEM) |
Gain of inhibition (%) | |
|---|---|---|---|
| Parent compound | Modified compound | ||
| MH | 68 (7) | 77 (9) | 9 |
| MH de-2-S | 27 (2) | 54 (6) | 27b |
| MH de-6-S | 5 (1) | 61 (5.8) | 56b |
| MH of 3 kDa | 37 (2) | 70 (8) | 33b |
| MH H2O2 | 57 (4) | 62 (4) | 5 |
| Enoxaparin | 64 (5) | 80 (3) | 14 |
| Bemiparin | 45 (2) | 31 (5) | −14 |
| Fondaparinux | 34 (0) | 11 (4) | −23b |
A panel of modified heparin compounds at 100 μg/ml each was tested for inhibition of P. falciparum in standard growth inhibition assays. Comparisons of the parent and periodate-treated compounds were made. Gain of inhibition was calculated as (percent inhibition of the modified compound − percent inhibition of parent compound). Positive values indicate increased inhibitory activity of the modified compound compared to that of the parent compound. Negative values indicate reduced inhibitory activity of the modified compound compared to that of the parent compound. Data are the mean percent inhibition ± SEM from two assays performed in duplicate. Abbreviation: MH, mucosal heparin (porcine).
Significant differences in inhibitory activity between parent and modified compounds (P > 0.05, corrected for multiple comparisons by the Holm-Sidak method).